Crosslink Capital, Inc. (“Crosslink”) was recently informed that someone or an organization has been impersonating it and one or more of its employees on the mobile application WhatsApp.
Crosslink does not market its services and Crosslink and its employees do not provide investment advice through WhatsApp or any similar social media messaging application, and anyone who does so purporting to act in Crosslink’s name or the name of any of its employees is not in any way connected to Crosslink or Crosslink Capital Management, LLC. Crosslink employees provide investment advice only through Crosslink. Crosslink provides investment advice only to investment funds or clients, in each case, with whom it has entered into a written contract. Crosslink does not provide investment or other advice to non-clients.
You can look up investment advisers and their registered persons at: https://adviserinfo.sec.gov/
For more information investing generally, please see: https://www.investor.gov/
May 16, 2019
It’s no secret that medication is prohibitively expensive for a lot of people and that the problem is only getting worse. While Medicare drugs rising at 10x the rate of inflation, for every drug that saw cost go down in 2018 there were 96 drugs that saw prices go up.
It gets even worse when it comes to specialty drugs, which are used to treat more complex conditions, such as rheumatoid arthritis and HIV. These drugs are only a fraction of the drugs that are dispensed, as they’re less commonly prescribed, but because of that they account for nearly half of the cost of prescription drugs.
It was the personal experience of Deepak Thomas that led him to found Phil, a company whose mission it is to make specialty drugs more available and affordable. Thomas, who previously had Lyme disease, told me that getting access to care, and to the medication he needed, was actually worse than dealing with the disease itself. Read rest here.